Intellia Therapeutics (NTLA) FCF Margin (2015 - 2026)
Intellia Therapeutics' (NTLA) quarterly FCF Margin came in at 779.81% in Q1 2026, up 11639.0% year-on-year from N/an in Q1 2025, and down 158.59% on a QoQ basis from 301.56% in Q4 2025.
Intellia Therapeutics (NTLA) FCF Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of FCF Margin data on file, last reported at 779.81% in Q1 2026.
- On a quarterly basis, FCF Margin rose 11639.0% year-over-year to 779.81% in Q1 2026; TTM through Mar 2026 was 551.05%, a 27254.0% increase from a year earlier, with the FY2025 full-year figure at 584.98%, up 1881.0% from the prior year.
- FCF Margin for Q1 2026 stood at 779.81%, down from 301.56% in the prior quarter.
- Over the last five years, FCF Margin for NTLA reached as high as 4283.46% in Q4 2023 and fell as low as 928.33% in Q3 2024.
- Historically, FCF Margin has averaged 402.77% across 5 years, with a median of 698.33% in 2023.
- Across the five-year window, FCF Margin jumped 494148 bps in 2023 and plunged 494680 bps in 2024, its largest moves.
- Year by year, FCF Margin stood at 658.01% in 2022, then surged by 751 bps to 4283.46% in 2023, then slumped by 115 bps to 663.34% in 2024, then jumped by 55 bps to 301.56% in 2025, then slumped by 159 bps to 779.81% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 779.81% in Q1 2026, 301.56% in Q4 2025, and 565.24% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Intellia Therapeutics | 1.32 Bn | 1.32 Bn | - | -779.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -779.81% |
| Dec 31, 2025 | -301.56% |
| Sep 30, 2025 | -565.24% |
| Jun 30, 2025 | -698.77% |
| Mar 31, 2025 | -896.20% |
| Dec 31, 2024 | -663.34% |
| Sep 30, 2024 | -928.33% |
| Jun 30, 2024 | -809.41% |
| Mar 31, 2024 | -425.67% |
| Dec 31, 2023 | 4,283.46% |
| Sep 30, 2023 | -881.53% |
| Jun 30, 2023 | -698.33% |
| Mar 31, 2023 | -895.23% |
| Dec 31, 2022 | -658.01% |
| Sep 30, 2022 | -580.10% |
| Jun 30, 2022 | -606.70% |
| Mar 31, 2022 | -742.29% |
| Dec 31, 2021 | -447.48% |
| Sep 30, 2021 | -965.57% |
| Jun 30, 2021 | -876.79% |